THE NUMBER NEEDED TO TREAT APPROACH- EVALUATING THE CLINICAL RELEVANCE OF FEXOFENADINE IN SEASONAL ALLERGIC RHINITIS
Author(s)
Crawford B1, Marquis P2, Offord S3, 1MAPI Values, Boston, MA, USA; 2MAPI Values, Lyon, France; 3Aventis Pharmaceuticals, Inc, Bridgewater, NJ, USA
The use of minimal important difference (MID) in quality of life assessment has grown recently in an effort to make measured changes more meaningful to the practicing physician. The use of MID, however, does not take into account the distribution of response, only the mean. OBJECTIVE: To examine the use of number needed to treat (NNT) in seasonal allergic rhinitis as a valid and more relevant approach to present data from clinical trials to physicians. METHODS: 538 subjects completed the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), a symptom questionnaire, and a self-reported change scale. These data were used to determine meaningful changes in the RQLQ and generate a 3x3 table to calculate the NNT. RESULTS: We examined data from the STAR study comparing fexofenadine, loratadine and placebo. The endpoint change in the RQLQ was stratified by self-assessed change to determine the NNT. This resulted in a NNT of 7.9 for fexofenadine, 63.5 for loratadine and 9.2 for fexofenadine versus loratadine. Thus, between 7-8 patients require treatment with fexofenadine for a patient to have a clinically meaningful improvement in quality of life while between 63-64 patients need to be treated with loratadine in order for one patient to obtain a significant improvement. Additional stratifications were examined to assess the effects of important differences on the NNT. Single digit NNT values, as seen with fexofenadine, strongly support the clinical relevance of the drug for improving patient quality of life.Loratadine Fexofenadine Improved Unchanged Deteriorated Improved 0.6089 0.0915 0.0279 Unchanged 0.1691 0.0254 0.0077 Deteriorated 0.0580 0.0087 0.002 CONCLUSIONS: The NNT approach represents an understandable approach to presenting quality of life data that may be more meaningful to practicing physicians.
Conference/Value in Health Info
2000-05, ISPOR 2000, Arlington, VA, USA
Value in Health, Vol. 3, No. 2 (March/April 2000)
Code
MI2
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Respiratory-Related Disorders